ATEZOLIZUMAB
atezolizumab 1.2 g/20 mL injection, 20 mL vial
ATEZOLIZUMAB (11277M)
11277M
Manner of administration:Injection
Restriction 10297
Indication: Locally advanced or metastatic non-small cell lung cancer
Treatment phase: Continuing treatment - 3 weekly treatment regimen
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 1200 mg | # of repeats: 7 | DPMA: $6,838.60 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Tecentriq
(atezolizumab 1.2 g/20 mL injection, 20 mL vial)
|
||||
